Efficacy and safety of switching from nevirapine immediate-release twice daily to nevirapine extended-release once daily in virologically suppressed HIV-infected patients: a retrospective cohort study in Taiwan

Efficacy and safety of switching from nevirapine immediate-release twice daily to nevirapine extended-release once daily in virologically suppressed HIV-infected patients: a retrospective cohort study in Taiwan

Abstract Background Whether the non-inferior efficacy and safety results of switching virologically suppressed HIV-1-infected patients from nevirapine immediate-release (NVP-IR) to NVP extended-release (NVP-XR) demonstrated in the TRANxITION study conducted in Europe and North America are also appli...

Full description

Bibliographic Details
Main Authors:	Chun-Yuan Lee, Hui-Min Chang, Calvin M Kunin, Susan Shin-Jung Lee, Yao-Shen Chen, Hung-Chin Tsai
Format:	Article
Language:	English
Published:	BMC 2017-04-01
Series:	BMC Infectious Diseases
Subjects:	Antiretroviral therapy Human immunodeficiency virus Nevirapine
Online Access:	http://link.springer.com/article/10.1186/s12879-017-2371-3

Similar Items

Long-term efficacy and safety of nevirapine-containing regimens in virologically suppressed patients: a 17-year follow up
by: Juan Tiraboschi, et al.
Published: (2019-11-01)

Combined antiretroviral therapy with nevirapine of HIV-infected adults
by: A V Kravchenko
Published: (2004-11-01)

Rapid Determination of Nevirapine in Human Plasma by High- Performance Liquid Chromatography
by: Kantima Sangsiriwut, et al.
Published: (2007-01-01)

Nevirapine- versus Efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and Tuberculosis infections in India: a multi-centre study
by: Sanjeev Sinha, et al.
Published: (2017-12-01)

Solid State Characterization and Dissolution Enhancement of Nevirapine Cocrystals
by: Prabhakar Panzade, et al.
Published: (2021-09-01)

The relation between efavirenz versus nevirapine and virologic failure in Johannesburg, South Africa
by: Kate Shearer, et al.
Published: (2014-01-01)

Efavirenz challenge in patients with nevirapine induced Stevens-Johnson Syndrome
by: Thandekile C. Manzini, et al.
Published: (2016-12-01)

Nevirapine-Induced Stevens–Johnson Syndrome in an HIV-Infected Patient: A Case Report From Uganda
by: Jayte M, et al.
Published: (2025-02-01)

Long-term efficacy and safety of once-daily nevirapine in combination with tenofovir and emtricitabine in the treatment of HIV-infected patients: a 72-week prospective multicenter study (TENOR-Trial)
by: Weberschock T, et al.
Published: (2009-12-01)

Factors associated with stockout of Nevirapine syrup in Oshana Region, Namibia
by: Emmanuel Magesa, et al.
Published: (2020-03-01)

Possible hepatotoxic consequence of nevirapine use in juvenile albino rats
by: Elias Adikwu, et al.
Published: (2017-08-01)

The antiretroviral efficacy of highly active antiretroviral therapy and plasma nevirapine concentrations in HIV-TB co-infected Indian patients receiving rifampicin based antituberculosis treatment
by: Sinha Sanjeev, et al.
Published: (2011-11-01)

Clinical utility and consumer considerations for the use of once-daily nevirapine extended release for HIV infection treatment
by: Pefura Yone EW, et al.
Published: (2012-12-01)

Nevirapine-induced side effects in pregnant women: experience of a brazilian university hospital
by: William Kondo, et al.

Perbandingan Penggunaan Efavirenz dan Nevirapine Terhadap Kolesterol LDL Pasien HIV/AIDS
by: Anggriani Yusi, et al.
Published: (2019-08-01)

Studies on some neuropharmacological properties of Nevirapine in mice
by: Peter Uchogu Ahmadu, et al.
Published: (2022-06-01)

Virological failure of staggered and simultaneous treatment interruption in HIV patients who began Efavirenz-based regimens after allergic reactions to nevirapine
by: Siripassorn Krittaecho, et al.
Published: (2013-01-01)

Green HPLC quantification method of lamivudine, zidovudine and nevirapine with identification of related substances in tablets
by: Ludivine Vieira-Sellaï, et al.
Published: (2022-07-01)

Pharmacological and clinical evidence of nevirapine immediate- and extended-release formulations
by: Ena J, et al.
Published: (2012-11-01)

Detection of HIV drug resistance mutations in pregnant women receiving single dose Nevirapine in south India
by: Mini S Jacob, et al.
Published: (2011-01-01)

AMELIORATIVE EFFECTS OF VITAMINS C AND E ON TENOFOVIR/NEVIRAPINE-INDUCED HEPATORENAL OXIDATIVE STRESS IN ALBINO RATS
by: Elias Adikwu, et al.
Published: (2016-10-01)

Severe eye complications from toxic epidermal necrolysis following initiation of Nevirapine based HAART regimen in a child with HIV infection: a case from Cameroon
by: Xavier Tchetnya, et al.
Published: (2018-03-01)

Nevirapine inhibits migration and invasion in dedifferentiated thyroid cancer cells
by: Hongxia Shang, et al.
Published: (2019-12-01)

2'-Deoxythymidine Adducts from the Anti-HIV Drug Nevirapine
by: M. Matilde Marques, et al.
Published: (2013-04-01)

Nevirapine in HIV maintenance therapy – can “old drugs” survive in current HIV management?
by: Julia Notter, et al.
Published: (2019-04-01)

Nevirapine-induced Stevens-Johnson syndrome in children living with HIV in South Africa
by: Jacques D. du Toit, et al.
Published: (2021-02-01)

Proportion of HIV exposed infants aged 0-6 months that missed nevirapine prophylaxis in Mulago National Referral Hospital, Uganda: a cross-sectional study
by: Nasambu Hellen, et al.
Published: (2024-07-01)

Clinical and genetic factors associated with increased risk of severe liver toxicity in a monocentric cohort of HIV positive patients receiving nevirapine-based antiretroviral therapy
by: Andrea Giacomelli, et al.
Published: (2018-11-01)

Covalent Histone Modification by an Electrophilic Derivative of the Anti-HIV Drug Nevirapine
by: Shrika G. Harjivan, et al.
Published: (2021-03-01)

Oxidation of 2-Hydroxynevirapine, a Phenolic Metabolite of the Anti-HIV Drug Nevirapine: Evidence for an Unusual Pyridine Ring Contraction
by: Frederick A. Beland, et al.
Published: (2012-03-01)

Time series analysis of Nevirapine syrup consumption in prevention of mother-tochild transmission and optimal supply chain model in Oshana region, Namibia
by: Emmanuel Magesa, et al.
Published: (2020-04-01)

Nevirapine induced toxic epidermal necrolysis and non-Hodgkin lymphoma in a Human Immunodeficiency Virus positive patient
by: Leelavathy Budamakuntla, et al.
Published: (2014-01-01)

Should nevirapine be used to prevent mother-to-child transmission of HIV among women of unknown serostatus?
by: Tin Tin Sint, et al.

Development and validation of a high performance liquid chromatography method to determine nevirapine in plasma in a resource-limited setting
by: Faithful Makita-Chingombe, et al.
Published: (2019-05-01)

LC-MS/MS Quantification of Nevirapine and Its Metabolites in Hair for Assessing Long-Term Adherence
by: Haoran Yang, et al.
Published: (2020-12-01)

Twice-Daily versus Once-Daily Pramipexole Extended Release Dosage Regimens in Parkinson’s Disease
by: Ji Young Yun, et al.
Published: (2017-01-01)

Growth patterns among HIV-exposed infants receiving nevirapine prophylaxis in Pune, India
by: Ram Malathi, et al.
Published: (2012-10-01)

New Crystal Forms for Biologically Active Compounds. Part 1: Noncovalent Interactions in Adducts of Nevirapine with XB Donors
by: Mariya A. Kryukova, et al.
Published: (2019-01-01)

Effect of ATP-Binding cassette, Sub-Family B polymorphism on plasma nevirapine and efavirenz levels in human immunodeficiency virus with tuberculosis-infected cases: A molecular structure analysis
by: Pathum Sookaromdee, et al.
Published: (2019-01-01)

Simultaneous quantitation of lamivudine, zidovudine and nevirapine in human plasma by liquid chromatography–tandem mass spectrometry and application to a pharmacokinetic study
by: Murali Krishna Matta, et al.
Published: (2012-10-01)